Skip to main content
NCBI home page
Journal of Medical Toxicology logoLink to Journal of Medical Toxicology
. 2010 Apr 7;6(2):217–229. doi: 10.1007/s13181-010-0053-2

Case Files of the New York City Poison Control Center: Paradichlorobenzene-Induced Leukoencephalopathy

Stephanie H Hernandez 1,2,✉, Sage W Wiener 3, Silas W Smith 1,2
PMCID: PMC3550295  PMID: 20373064

Full Text

The Full Text of this article is available as a PDF (288.8 KB).

Acknowledgements

This case was presented at the ACMT Medical Toxicology 11th Annual CPC Competition at the 2009 North American Congress of Clinical Toxicology Annual Meeting, San Antonio, TX, USA, September 22, 2009.

Footnotes

The authors have neither financial interest in any commercial products mentioned nor the companies that produce them.

No outside funding was received.

References

  • 1.Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. doi: 10.1056/NEJM199602223340803. [DOI] [PubMed] [Google Scholar]
  • 2.Sharshar T, Gray F, Poron F, Raphael JC, Gajdos P, Annane D. Multifocal necrotizing leukoencephalopathy in septic shock. Crit Care Med. 2002;30:2371–2375. doi: 10.1097/00003246-200210000-00031. [DOI] [PubMed] [Google Scholar]
  • 3.van der Knaap MS, Breiter SN, Naidu S, Hart AA, Valk J. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213:121–133. doi: 10.1148/radiology.213.1.r99se01121. [DOI] [PubMed] [Google Scholar]
  • 4.Hesselink JR. Differential diagnostic approach to MR imaging of white matter diseases. Top Magn Reson Imaging. 2006;17:243–263. doi: 10.1097/01.rmr.0000248666.91834.af. [DOI] [PubMed] [Google Scholar]
  • 5.Costello DJ, Eichler AF, Eichler FS. Leukodystrophies: classification, diagnosis, and treatment. Neurologist. 2009;15:319–328. doi: 10.1097/NRL.0b013e3181b287c8. [DOI] [PubMed] [Google Scholar]
  • 6.Vanderver A. Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease. Curr Neurol Neurosci Rep. 2005;5:110–118. doi: 10.1007/s11910-005-0008-1. [DOI] [PubMed] [Google Scholar]
  • 7.Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991;70:229–245. doi: 10.1097/00005792-199107000-00001. [DOI] [PubMed] [Google Scholar]
  • 8.Chatterjee A, Yapundich R, Palmer CA, Marson DC, Mitchell GW. Leukoencephalopathy associated with cobalamin deficiency. Neurology. 1996;46:832–834. doi: 10.1212/wnl.46.3.832. [DOI] [PubMed] [Google Scholar]
  • 9.Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5:949–960. doi: 10.1016/S1474-4422(06)70598-1. [DOI] [PubMed] [Google Scholar]
  • 10.Celik O, Hascalik S. Reversible posterior leukoencephalopathy in eclampsia. Int J Gynaecol Obstet. 2003;82:67–69. doi: 10.1016/s0020-7292(03)00128-0. [DOI] [PubMed] [Google Scholar]
  • 11.Rosenberg GA. Inflammation and white matter damage in vascular cognitive impairment. Stroke. 2009;40:S20–S23. doi: 10.1161/STROKEAHA.108.533133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology. 2004;62:494–497. doi: 10.1212/01.wnl.0000106951.94624.df. [DOI] [PubMed] [Google Scholar]
  • 13.Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009;9:625–636. doi: 10.1016/S1473-3099(09)70226-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, Frank LR, Grant I, Charter Group White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirology. 2009;15:187–195. doi: 10.1080/13550280902769756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Souraud JB, Faivre A, Waku-Kouomou D, Gaillard T, Aouad N, Meaudre E, Wild FT, Fouet B, Soulard R. Adult fulminant subacute sclerosing panencephalitis: pathological and molecular studies—a case report. Clin Neuropathol. 2009;28:213–218. doi: 10.5414/npp28213. [DOI] [PubMed] [Google Scholar]
  • 16.Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009;31:439–453. doi: 10.1007/s00281-009-0178-z. [DOI] [PubMed] [Google Scholar]
  • 17.Canellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology. 2007;49:393–409. doi: 10.1007/s00234-007-0216-2. [DOI] [PubMed] [Google Scholar]
  • 18.Fleming FJ, Vytopil M, Chaitow J, Jones HR, Jr, Darras BT, Ryan MM. Thalidomide neuropathy in childhood. Neuromuscul Disord. 2005;15:172–176. doi: 10.1016/j.nmd.2004.10.005. [DOI] [PubMed] [Google Scholar]
  • 19.Burns TM, Shneker BF, Juel VC. Gasoline sniffing multifocal neuropathy. Pediatr Neurol. 2001;25:419–421. doi: 10.1016/s0887-8994(01)00334-4. [DOI] [PubMed] [Google Scholar]
  • 20.Smith AG, Albers JW. n-Hexane neuropathy due to rubber cement sniffing. Muscle Nerve. 1997;20:1445–1450. doi: 10.1002/(sici)1097-4598(199711)20:11<1445::aid-mus13>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  • 21.Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27–46. doi: 10.1111/j.1529-8027.2008.00156.x. [DOI] [PubMed] [Google Scholar]
  • 22.Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology. 1992;42:1367–1370. doi: 10.1212/wnl.42.7.1367. [DOI] [PubMed] [Google Scholar]
  • 23.Berger AR, Arezzo JC, Schaumburg HH, Skowron G, Merigan T, Bozzette S, Richman D, Soo W. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993;43:358–362. doi: 10.1212/wnl.43.2.358. [DOI] [PubMed] [Google Scholar]
  • 24.Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22. doi: 10.1186/jbiol50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627–642. doi: 10.1200/JCO.1994.12.3.627. [DOI] [PubMed] [Google Scholar]
  • 26.Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist. 2003;9:180–188. doi: 10.1097/01.nrl.0000080951.78533.c4. [DOI] [PubMed] [Google Scholar]
  • 27.Blaes AH, Santa-Cruz KS, Lee CK, Hui SK, Peterson BA. Necrotizing leukoencephalopathy following CHOP chemotherapy. Leuk Res. 2008;32:1611–1614. doi: 10.1016/j.leukres.2008.02.014. [DOI] [PubMed] [Google Scholar]
  • 28.Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG, Rodriguez M. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992;31:262–267. doi: 10.1002/ana.410310306. [DOI] [PubMed] [Google Scholar]
  • 29.Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, Yoshida M, Kaneda M, Suzuki Y, Miyasaka K. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology. 2003;45:493–497. doi: 10.1007/s00234-003-0983-3. [DOI] [PubMed] [Google Scholar]
  • 30.Garg RK. Postpartum posterior leukoencephalopathy syndrome. J Assoc Phys India. 2003;51:211–213. [PubMed] [Google Scholar]
  • 31.Ricard D, Taillia H, Renard JL. Brain damage from anticancer treatments in adults. Curr Opin Oncol. 2009;21:559–565. doi: 10.1097/CCO.0b013e328330c669. [DOI] [PubMed] [Google Scholar]
  • 32.Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol. 1999;14:277–281. doi: 10.1177/088307389901400502. [DOI] [PubMed] [Google Scholar]
  • 33.Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–417. [PMC free article] [PubMed] [Google Scholar]
  • 34.Kwon EJ, Kim SW, Kim KK, Seo HS, Kim do Y. A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat. 2009;41:53–55. doi: 10.4143/crt.2009.41.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rajasekhar A, George TJ., Jr Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007;12:1332–1335. doi: 10.1634/theoncologist.12-11-1332. [DOI] [PubMed] [Google Scholar]
  • 36.Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol. 2001;12:1327–1329. doi: 10.1023/a:1012248800195. [DOI] [PubMed] [Google Scholar]
  • 37.Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol. 2006;36:205–212. doi: 10.1007/s00247-005-0015-z. [DOI] [PubMed] [Google Scholar]
  • 38.Kelly K, Kalachand R, Murphy P. Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol. 2008;141:566. doi: 10.1111/j.1365-2141.2008.07088.x. [DOI] [PubMed] [Google Scholar]
  • 39.Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25:3559. doi: 10.1200/JCO.2007.12.8710. [DOI] [PubMed] [Google Scholar]
  • 40.Hissink AM, Dunnewijk R, van Ommen B, van Bladeren PJ. Kinetics and metabolism of 1,4-dichlorobenzene in male Wistar rats: no evidence for quinone metabolites. Chem Biol Interact. 1997;103:17–33. doi: 10.1016/s0009-2797(96)03746-5. [DOI] [PubMed] [Google Scholar]
  • 41.Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. l-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg. 2002;37:203–205. doi: 10.1159/000065395. [DOI] [PubMed] [Google Scholar]
  • 42.Tsagalou EP, Anastasiou-Nana MI, Margari ZJ, Vassilopoulos D. Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation. J Heart Lung Transplant. 2007;26:661–664. doi: 10.1016/j.healun.2007.03.008. [DOI] [PubMed] [Google Scholar]
  • 43.Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, Yamashiro DJ, Bender JL. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer. 2009;52:669–671. doi: 10.1002/pbc.21866. [DOI] [PubMed] [Google Scholar]
  • 44.Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol. 2007;25:2484–2486. doi: 10.1200/JCO.2007.10.9991. [DOI] [PubMed] [Google Scholar]
  • 45.Yoshimoto T, Yagi K, Inoue M, Okamura T, Yasui M, Cyayama K, Nakano T, Tsuchiya H, Kawa K. Leukoencephalopathy probably caused by tacrolimus hydrate after stem cell transplantation in a girl with MDS 7 monosomy. Rinsho Ketsueki. 1997;38:616–621. [PubMed] [Google Scholar]
  • 46.Kastrup O, Diener HC. TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol. 2008;255:452–453. doi: 10.1007/s00415-008-0732-y. [DOI] [PubMed] [Google Scholar]
  • 47.Kamar N, Kany M, Bories P, Ribes D, Izopet J, Durand D, Rostaing L. Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis. 2001;37(E29):1–6. doi: 10.1016/s0272-6386(01)90015-0. [DOI] [PubMed] [Google Scholar]
  • 48.Re D, Bamborschke S, Feiden W, Schroder R, Lehrke R, Diehl V, Tesch H. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant. 1999;23:295–298. doi: 10.1038/sj.bmt.1701568. [DOI] [PubMed] [Google Scholar]
  • 49.de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB, Jr, Silva LS. Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. Int Urol Nephrol. 2008;40:1095–1098. doi: 10.1007/s11255-008-9431-y. [DOI] [PubMed] [Google Scholar]
  • 50.Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology. 1997;49:686–689. doi: 10.1212/wnl.49.3.686. [DOI] [PubMed] [Google Scholar]
  • 51.Kunschner L, Scott TF. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology. 2005;65:1510. doi: 10.1212/01.wnl.0000183064.10227.b5. [DOI] [PubMed] [Google Scholar]
  • 52.Przepiorka D, Jaeckle KA, Birdwell RR, Fuller GN, Kumar AJ, Huh YO, McCutcheon I. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 1997;20:983–987. doi: 10.1038/sj.bmt.1701010. [DOI] [PubMed] [Google Scholar]
  • 53.Xu N, Zhou W, Li S, Zhou G, Zhang N, Liang J. Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J Neuroimaging. 2009;19:326–331. doi: 10.1111/j.1552-6569.2008.00344.x. [DOI] [PubMed] [Google Scholar]
  • 54.Wu VC, Huang JW, Lien HC, Hsieh ST, Liu HM, Yang CC, Lin YH, Hwang JJ, Wu KD. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 2006;85:203–213. doi: 10.1097/01.md.0000230250.95281.60. [DOI] [PubMed] [Google Scholar]
  • 55.Liu JS, Chang YY, Chen WH, Chen SS. Amphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitis. J Formos Med Assoc. 1995;94:432–434. [PubMed] [Google Scholar]
  • 56.Walker RW, Rosenblum MK. Amphotericin B-associated leukoencephalopathy. Neurology. 1992;42:2005–2010. doi: 10.1212/wnl.42.10.2005. [DOI] [PubMed] [Google Scholar]
  • 57.Ferry T, Ponceau B, Simon M, Issartel B, Petiot P, Boibieux A, Biron F, Chidiac C, Peyramond D. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection. 2005;33:151–154. doi: 10.1007/s15010-005-4057-9. [DOI] [PubMed] [Google Scholar]
  • 58.Mahad DJ, Hellden A, Jarvis J, Mitra D, Gholkar A, Chinnery PF. Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry. 2005;76:1308–1309. doi: 10.1136/jnnp.2004.059824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Shuman RM, Leech RW, Alvord ECJ. Neurotoxicity of hexachlorophene in humans. II. A clinicopathological study of 46 premature infants. Arch Neurol. 1975;32:320–325. doi: 10.1001/archneur.1975.00490470064009. [DOI] [PubMed] [Google Scholar]
  • 60.Nishimune T, Watanabe Y, Okazaki H, Akai H. Thiamin is decomposed due to Anaphe spp. entomophagy in seasonal ataxia patients in Nigeria. J Nutr. 2000;130:1625–1628. doi: 10.1093/jn/130.6.1625. [DOI] [PubMed] [Google Scholar]
  • 61.Kumar N. Neurologic presentations of nutritional deficiencies. Neurol Clin. 2010;28:107–170. doi: 10.1016/j.ncl.2009.09.006. [DOI] [PubMed] [Google Scholar]
  • 62.Spampinato MV, Castillo M, Rojas R, Palacios E, Frascheri L, Descartes F. Magnetic resonance imaging findings in substance abuse: alcohol and alcoholism and syndromes associated with alcohol abuse. Top Magn Reson Imaging. 2005;16:223–230. doi: 10.1097/01.rmr.0000192175.26243.a7. [DOI] [PubMed] [Google Scholar]
  • 63.Rubinstein D, Escott E, Kelly JP. Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. AJNR Am J Neuroradiol. 1995;16:1492–1494. [PMC free article] [PubMed] [Google Scholar]
  • 64.Freilich BM, Altun Z, Ramesar C, Medalia A. Neuropsychological sequelae of ethylene glycol intoxication: a case study. Appl Neuropsychol. 2007;14:56–61. doi: 10.1080/09084280701280494. [DOI] [PubMed] [Google Scholar]
  • 65.Hantson P, Duprez T. The value of morphological neuroimaging after acute exposure to toxic substances. Toxicol Rev. 2006;25:87–98. doi: 10.2165/00139709-200625020-00003. [DOI] [PubMed] [Google Scholar]
  • 66.Salgado RA, Jorens PG, Baar I, Cras P, Hans G, Parizel PM. Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings. AJNR Am J Neuroradiol. 2009;31:565–566. doi: 10.3174/ajnr.A1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Anselmo M, Campos Rainho A, do Carmo Vale M, Estrada J, Valente R, Correia M, Vieira JP, Barata D. Methadone intoxication in a child: toxic encephalopathy? J Child Neurol. 2006;21:618–620. doi: 10.1177/08830738060210071101. [DOI] [PubMed] [Google Scholar]
  • 68.Wolters EC, van Wijngaarden GK, Stam FC. Leukoencephalopathy after inhaling “heroin” pyrosylate. Lancet. 1982;2:1233–1237. doi: 10.1016/s0140-6736(82)90101-5. [DOI] [PubMed] [Google Scholar]
  • 69.Kriegstein AR, Shungu DC, Millar WS, Armitage BA, Brust JC, Chillrud S, Goldman J, Lynch T. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (“chasing the dragon”) Neurology. 1999;53:1765–1773. doi: 10.1212/wnl.53.8.1765. [DOI] [PubMed] [Google Scholar]
  • 70.Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol. 2008;63:146–152. doi: 10.1016/j.crad.2007.07.021. [DOI] [PubMed] [Google Scholar]
  • 71.Hagel J, Andrews G, Vertinsky T, Heran MK, Keogh C. “Chasing the dragon”—imaging of heroin inhalation leukoencephalopathy. Can Assoc Radiol J. 2005;56:199–203. [PubMed] [Google Scholar]
  • 72.McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol. 2009;193:192–206. doi: 10.2214/AJR.08.1176. [DOI] [PubMed] [Google Scholar]
  • 73.Ryan A, Molloy FM, Farrell MA, Hutchinson M. Fatal toxic leukoencephalopathy: clinical, radiological, and necropsy findings in two patients. J Neurol Neurosurg Psychiatry. 2005;76:1014–1016. doi: 10.1136/jnnp.2004.047134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Rosenberg NL, Kleinschmidt-DeMasters BK, Davis KA, Dreisbach JN, Hormes JT, Filley CM. Toluene abuse causes diffuse central nervous system white matter changes. Ann Neurol. 1988;23:611–614. doi: 10.1002/ana.410230614. [DOI] [PubMed] [Google Scholar]
  • 75.Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol. 2004;63:1–12. doi: 10.1093/jnen/63.1.1. [DOI] [PubMed] [Google Scholar]
  • 76.Bickel M, Ditting T, Watz H, Roesler A, Weidauer S, Jacobi V, Gueller S, Betz C, Fichtlscherer S, Stein J. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after “magic mushroom” abuse. Eur J Emerg Med. 2005;12:306–308. doi: 10.1097/00063110-200512000-00011. [DOI] [PubMed] [Google Scholar]
  • 77.Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol. 2008;3:1852–1860. doi: 10.2215/CJN.02080508. [DOI] [PubMed] [Google Scholar]
  • 78.Cowan RL, Roberts DM, Joers JM. Neuroimaging in human MDMA (ecstasy) users. Ann N Y Acad Sci. 2008;1139:291–298. doi: 10.1196/annals.1432.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Hwang CH. The sequential magnetic resonance images of tri-methyl tin leukoencephalopathy. Neurol Sci. 2009;30:153–158. doi: 10.1007/s10072-009-0028-8. [DOI] [PubMed] [Google Scholar]
  • 80.Huang CC. Carbon disulfide neurotoxicity: Taiwan experience. Acta Neurol Taiwan. 2004;13:3–9. [PubMed] [Google Scholar]
  • 81.Ku MC, Huang CC, Kuo HC, Yen TC, Chen CJ, Shih TS, Chang HY. Diffuse white matter lesions in carbon disulfide intoxication: microangiopathy or demyelination. Eur Neurol. 2003;50:220–224. doi: 10.1159/000073863. [DOI] [PubMed] [Google Scholar]
  • 82.Parkinson RB, Hopkins RO, Cleavinger HB, Weaver LK, Victoroff J, Foley JF, Bigler ED. White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning. Neurology. 2002;58:1525–1532. doi: 10.1212/wnl.58.10.1525. [DOI] [PubMed] [Google Scholar]
  • 83.Miura T, Mitomo M, Kawai R, Harada K. CT of the brain in acute carbon monoxide intoxication: characteristic features and prognosis. AJNR Am J Neuroradiol. 1985;6:739–742. [PMC free article] [PubMed] [Google Scholar]
  • 84.Yoshida T, Andoh K, Fukuhara M. Urinary 2,5-dichlorophenol as biological index for p-dichlorobenzene exposure in the general population. Arch Environ Contam Toxicol. 2002;43:481–485. doi: 10.1007/s00244-002-1228-x. [DOI] [PubMed] [Google Scholar]
  • 85.Morita M, Ohi G. Para-dichlorobenzene in human tissue and atmosphere in Tokyo metropolitan area. Environ Pollut. 1975;8:269. [Google Scholar]
  • 86.Hissink AM, Oudshoorn MJ, Van Ommen B, Van Bladeren PJ. Species and strain differences in the hepatic cytochrome P450-mediated biotransformation of 1,4-dichlorobenzene. Toxicol Appl Pharmacol. 1997;145:1–9. doi: 10.1006/taap.1997.8153. [DOI] [PubMed] [Google Scholar]
  • 87.Bogaards JJ, van Ommen B, Wolf CR, van Bladeren PJ. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol Appl Pharmacol. 1995;132:44–52. doi: 10.1006/taap.1995.1085. [DOI] [PubMed] [Google Scholar]
  • 88.Hawkins DR, Chasseaud LF, Woodhouse RN, Cresswell DG. The distribution excretion and biotransformation of p-dichloro[14C] benzene in rats after repeated inhalation, oral and subcutaneous doses. Xenobiotica. 1980;10:81–95. doi: 10.3109/00498258009033734. [DOI] [PubMed] [Google Scholar]
  • 89.Klos C, Dekant W. Comparative metabolism of the renal carcinogen 1,4-dichlorobenzene in rat: identification and quantitation of novel metabolites. Xenobiotica. 1994;24:965–976. doi: 10.3109/00498259409043294. [DOI] [PubMed] [Google Scholar]
  • 90.Hill RH, Jr, Ashley DL, Head SL, Needham LL, Pirkle JL. p-Dichlorobenzene exposure among 1,000 adults in the United States. Arch Environ Health. 1995;50:277–280. doi: 10.1080/00039896.1995.9935954. [DOI] [PubMed] [Google Scholar]
  • 91.Yoshida T, Andoh K, Kosaka H, Kumagai S, Matsunaga I, Akasaka S, Nakamura S, Oda H, Fukuhara M. Inhalation toxicokinetics of p-dichlorobenzene and daily absorption and internal accumulation in chronic low-level exposure to humans. Arch Toxicol. 2002;76:306–315. doi: 10.1007/s00204-002-0341-y. [DOI] [PubMed] [Google Scholar]
  • 92.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1999) Dichlorobenzenes. In: IARC monographs on the evaluation of carcinogenic risks to humans. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances, vol. 73. IARC Press, Lyons, pp 223–276
  • 93.Eldridge SR, Goldsworthy TL, Popp JA, Butterworth BE. Mitogenic stimulation of hepatocellular proliferation in rodents following 1,4-dichlorobenzene administration. Carcinogenesis. 1992;13:409–415. doi: 10.1093/carcin/13.3.409. [DOI] [PubMed] [Google Scholar]
  • 94.Lake BG, Cunninghame ME, Price RJ. Comparison of the hepatic and renal effects of 1,4-dichlorobenzene in the rat and mouse. Fundam Appl Toxicol. 1997;39:67–75. doi: 10.1006/faat.1997.2350. [DOI] [PubMed] [Google Scholar]
  • 95.Aiso S, Arito H, Nishizawa T, Nagano K, Yamamoto S, Matsushima T. Thirteen-week inhalation toxicity of p-dichlorobenzene in mice and rats. J Occup Health. 2005;47:249–260. doi: 10.1539/joh.47.249. [DOI] [PubMed] [Google Scholar]
  • 96.Umemura T, Kodama Y, Kurokawa Y, Williams GM. Lack of oxidative DNA damage or initiation of carcinogenesis in the kidneys of male F344 rats given subchronic exposure to p-dichlorobenzene (pDCB) at a carcinogenic dose. Arch Toxicol. 2000;74:54–59. doi: 10.1007/s002040050652. [DOI] [PubMed] [Google Scholar]
  • 97.Charbonneau M, Strasser J, Jr, Lock EA, Turner MJ, Jr, Swenberg JA. Involvement of reversible binding to alpha 2u-globulin in 1,4-dichlorobenzene-induced nephrotoxicity. Toxicol Appl Pharmacol. 1989;99:122–132. doi: 10.1016/0041-008x(89)90117-8. [DOI] [PubMed] [Google Scholar]
  • 98.Zupko AG, Edwards LD. A toxicological study of p-dichlorobenzene. J Am Pharm Assoc. 1949;38:124–131. doi: 10.1002/jps.3030380304. [DOI] [PubMed] [Google Scholar]
  • 99.Hollingsworth RL, Hoyle HR, Oyen F, Rowe VK, Spencer HC. Toxicity of paradichlorobenzene; determinations on experimental animals and human subjects. AMA Arch Ind Health. 1956;14:138–147. [PubMed] [Google Scholar]
  • 100.EPA US. Toxicological review and summary documents for dichlorobenzenes (external review draft). EPA/635/R-03/015. Cincinnati: US Environmental Protection Agency; 2003. [Google Scholar]
  • 101.Hallowell M. Acute haemolytic anaemia following the ingestion of paradichlorobenzene. Arch Dis Child. 1959;34:74–77. doi: 10.1136/adc.34.173.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Campbell DM, Davidson RJ. Toxic haemolytic anaemia in pregnancy due to a pica for paradichlorobenzene. J Obstet Gynaecol Br Commonw. 1970;77:657–659. doi: 10.1111/j.1471-0528.1970.tb03588.x. [DOI] [PubMed] [Google Scholar]
  • 103.Harden RA, Baetjer AM. Aplastic anemia following exposure to paradichlorobenzene and naphthalene. J Occup Med. 1978;20:820–822. [PubMed] [Google Scholar]
  • 104.Wallgren K. Chronische Vergiftungen bel der Herstellung von Mottenmitteln, die grosstenteils aus paradichlorobenzol bestehen. Zentralbl Arbeitsmed Arbeitsschutz. 1953;3:14–15. [Google Scholar]
  • 105.Petit G, Champeix J. Existe-t-il une intoxication par le paradichlorobenzene? Arch Mal Prof. 1948;9:311–313. [PubMed] [Google Scholar]
  • 106.Girard R, Toldt F, Martin P, Bourret J. Hemopathies graves et exposition a des derives chlores du benzene (a propas de 7 cas) J Med (Lyon) 1969;50:771–773. [PubMed] [Google Scholar]
  • 107.Weller RW, Crellin AJ. Pulmonary granulomatosis following extensive use of paradichlorobenzene. AMA Arch Intern Med. 1953;91:408–413. doi: 10.1001/archinte.1953.00240150127012. [DOI] [PubMed] [Google Scholar]
  • 108.Cotter LH. Paradichlorobenzene poisoning from insecticides. N Y State J Med. 1953;53:1690–1692. [PubMed] [Google Scholar]
  • 109.Sumers J, Fuhrman M, Kelman A. Hepatitis with concomitant esophageal varices following exposure to moth ball vapors. N Y State J Med. 1952;52:1048–1049. [PubMed] [Google Scholar]
  • 110.Nalbandian RM, Pearce JF. Allergic purpura induced by exposure to p-dichlorobenzene. Confirmation by indirect basophil degranulation test. JAMA. 1965;194:828–829. [PubMed] [Google Scholar]
  • 111.Murray SB, Dwight-Johnson M, Levy MR. Mothball induced encephalopathy presenting as depression: it’s all in the history. Gen Hosp Psychiatry. 2009 doi: 10.1016/j.genhosppsych.2009.04.008. [DOI] [PubMed] [Google Scholar]
  • 112.Kumar N, Dale LC, Wijdicks EF. Mothball mayhem: relapsing toxic leukoencephalopathy due to p-dichlorobenzene neurotoxicity. Ann Intern Med. 2009;150:362–363. doi: 10.7326/0003-4819-150-5-200903030-00025. [DOI] [PubMed] [Google Scholar]
  • 113.Cheong R, Wilson RK, Cortese IC, Newman-Toker DE. Mothball withdrawal encephalopathy: case report and review of paradichlorobenzene neurotoxicity. Subst Abus. 2006;27:63–67. doi: 10.1300/j465v27n04_08. [DOI] [PubMed] [Google Scholar]
  • 114.Avila E, Schraeder P, Belliappa A, Faro S. Pica with paradichlorobenzene mothball ingestion associated with toxic leukoencephalopathy. J Neuroimaging. 2006;16:78–81. doi: 10.1177/1051228405280171. [DOI] [PubMed] [Google Scholar]
  • 115.Feuillet L, Mallet S, Spadari M. Twin girls with neurocutaneous symptoms caused by mothball intoxication. N Engl J Med. 2006;355:423–424. doi: 10.1056/NEJMc060329. [DOI] [PubMed] [Google Scholar]
  • 116.Weintraub E, Gandhi D, Robinson C. Medical complications due to mothball abuse. South Med J. 2000;93:427–429. [PubMed] [Google Scholar]
  • 117.Reygagne A, Garnier R, Chataigner D, Echenne B, Efthymiou ML. Encephalopathy due to repeated voluntary inhalation of paradichlorobenzene. J Toxicol Clin Exp. 1992;12:247–250. [PubMed] [Google Scholar]
  • 118.Miyai I, Hirono N, Fujita M, Kameyama M. Reversible ataxia following chronic exposure to paradichlorobenzene. J Neurol Neurosurg Psychiatry. 1988;51:453–454. doi: 10.1136/jnnp.51.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Frank S, Cohen HJ. Fixed drug eruption due to paradichlorobenzene. N Y State J Med. 1961;61:4079. [Google Scholar]
  • 120.Hill RH, Jr, To T, Holler JS, Fast DM, Smith SJ, Needham LL, Binder S. Residues of chlorinated phenols and phenoxy acid herbicides in the urine of Arkansas children. Arch Environ Contam Toxicol. 1989;18:469–474. doi: 10.1007/BF01055011. [DOI] [PubMed] [Google Scholar]
  • 121.Angerer J, Heinzow B, Schaller K, Weltle D. Determination of environmental caused chlorophenol levels in urine of the general population. Fresenius' J Anal Chem. 1992;342:433–438. [Google Scholar]
  • 122.Morita S, Miwa H, Kihira T, Kondo T. Cerebellar ataxia and leukoencephalopathy associated with cobalamin deficiency. J Neurol Sci. 2003;216:183–184. doi: 10.1016/s0022-510x(03)00219-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer

RESOURCES